**Patient**: Alexander Chen (DOB 1992-01-07)  
**MRN**: 472951  
**Admission**: 2024-03-20 | **Discharge**: 2024-03-27  
**Physicians**: Dr. K. Mitchell (Hematology/Oncology), Dr. L. Ramirez (Infectious Disease), Dr. P. Wong (Pulmonology)

**Discharge diagnosis: Metastatic seminoma with febrile neutropenia after cycle 3 PEB**

**1. Oncological Diagnosis**

* **Primary**: Pure Testicular Seminoma, Right Testis, pT2N3M1b, Stage IIIA
* **Diagnosis Date**: January 10, 2024
* **Histology**: Right Radical Orchiectomy (1/8/24): Pure seminoma, 4.2 cm, positive LVI, negative margins
* **Risk**: IGCCCG Intermediate Prognosis Group
* **Initial Imaging**: Multiple retroperitoneal nodes (largest 6.8 × 4.5 cm), bilateral pulmonary nodules (0.6-1.2 cm), liver metastasis (1.2 cm)
* **Markers at Diagnosis**: AFP 5.2 ng/mL (normal), β-hCG 35 mIU/mL (elevated), LDH 525 U/L (elevated)

**2. Treatment History**

* **Surgery**: Right Radical Inguinal Orchiectomy (1/8/24)
* **PEB Cycle 1** (1/22-26/24): Grade 2 nausea/vomiting, Grade 1 neuropathy
* **PEB Cycle 2** (2/19-23/24): Grade 2 nausea/vomiting, Grade 1-2 neuropathy, Grade 1 tinnitus
* **PEB Cycle 3** (3/13-17/24): Febrile neutropenia on Day 7 (current admission)
* **Response**: 55% reduction after Cycle 2; Markers pre-Cycle 3: AFP 3.8 ng/mL, β-hCG <2 mIU/mL, LDH 245 U/L

**3. Current Admission**

* **Reason**: Febrile neutropenia (38.9°C, ANC 0.2 × 10^9/L) on Day 7 post-PEB
* **Key Findings**:
  + Blood cultures: Hickman catheter positive for MRSE (peripheral negative)
  + Hickman catheter removed (3/21/24), tip culture confirmed MRSE
  + CT chest: No pneumonia, stable to decreased pulmonary nodules
  + ANC nadir 0.1 × 10^9/L (Day 10 post-chemo)
  + Grade 2 mucositis developed during hospitalization
  + Mild reversible renal dysfunction (Cr 1.3 mg/dL, baseline 0.9)
  + Bleomycin Day 8 and 15 held due to neutropenic fever
* **Treatment**:
  + Piperacillin-tazobactam 4.5g IV q6h
  + Vancomycin 15 mg/kg IV q12h
  + Filgrastim 5 mcg/kg SC daily (started hospital day 2)
  + Electrolyte repletion (Mg, K)
  + Supportive care for mucositis

**4. Comorbidities**

* Mild asthma
* Generalized anxiety disorder
* Hyperlipidemia
* History of kidney stones
* Seasonal allergies

**5. Discharge Medications**

* Vancomycin 15 mg/kg IV BID for 9 more days (total 14 days) with home infusions, levels q2days
* Montelukast 10 mg PO daily
* Fluticasone/salmeterol 250/50 mcg inhaled BID
* Loratadine 10 mg PO daily
* Atorvastatin 20 mg PO daily
* Escitalopram 10 mg PO daily
* Ondansetron 8 mg PO q8h PRN
* Oxycodone 5 mg PO q6h PRN
* Magic mouthwash 5-10 mL QID PRN
* Magnesium oxide 400 mg PO BID × 7 days
* Potassium chloride 20 mEq PO daily × 5 days

**6. Follow-up Plan**

* **Oncology**: Dr. K. Mitchell in 1 week (4/3/24)
  + CBC, CMP, Mg, K+ twice weekly until recovery
  + Tumor markers prior to Cycle 4
  + PEB Cycle 4 tentatively scheduled for 4/10-14/24 with modifications:
    - Prophylactic G-CSF starting Day 6
    - Consider 25% etoposide dose reduction
    - PICC line placement planned for 4/9/24
* **Infectious Disease**: Dr. L. Ramirez on 4/3/24
* **Pulmonology**: Dr. P. Wong before Cycle 4 for PFTs with DLCO
* **Imaging**: Restaging CT after completion of therapy (~May 2024)

**7. Lab Values (Admission → Nadir/Peak → Discharge)**

* WBC: 1.2 → 0.6 → 3.8 × 10^9/L
* ANC: 0.2 → 0.1 → 2.8 × 10^9/L
* Hemoglobin: 10.8 → 9.5 → 10.2 g/dL
* Platelets: 105 → 58 → 98 × 10^9/L
* Creatinine: 1.1 → 1.3 → 0.9 mg/dL
* Potassium: 3.4 → 3.2 → 3.8 mEq/L
* Magnesium: 1.5 → 1.4 → 1.9 mg/dL
* CRP: 85 → 120 → 22 mg/L
* Procalcitonin: 2.8 → - → 0.4 ng/mL
* Blood Culture (Hickman): Positive MRSE → No growth
* Blood Culture (Peripheral): No growth → No growth

**Electronically Signed By**:  
Dr. K. Mitchell (Hematology/Oncology) - 2024-03-27 14:15  
Dr. L. Ramirez (Infectious Disease) - 2024-03-27 13:30  
Dr. P. Wong (Pulmonology) - 2024-03-27 12:45